BioNTech and Pfizer’s Covid-19 vaccine trial show positive results

A coronavirus vaccine from the drug giant Pfizer and the biotech firm BioNTech has shown positive trial results, producing immune defenses in healthy patients, according to initial data released by the company.
July 02, 2020 | 08:39
vietnam prepares to put indigenous covid 19 vaccine on human trial Vietnam prepares to put indigenous Covid-19 vaccine on human trial
us coronavirus cases rise by 47000 the biggest number of one day spike US coronavirus cases rise by 47,000, the biggest number of one-day spike
international organizations seek cooperation with vietnam in covid 19 vaccine producing International organizations seek cooperation with Vietnam in COVID-19 vaccine producing

It is reported that 24 people between the ages of 18 and 55 who took two doses of the vaccine had generated antibodies within four weeks of their first injection. There were a total of 45 people participating in the study, with some receiving placebos and others getting higher doses of the vaccine.

Subjects in BioNTech’s US trial were injected with two doses of 10 micrograms or 30 micrograms each, three weeks apart, and were observed to have developed the highest level of potential immunity seven days after the booster injection.

The current study did not comprise pregnant women, and no other information on the ethnic diversity of participants was noted, although the paper does say that future studies will need to include a more diverse group.

2219 10
In the clinical study, 24 people between the ages of 18 and 55 who received two doses of the vaccine had “significantly elevated” antibodies within four weeks of their first injection. Photograph: IStock

With promising preliminary results, BioNTech and Pfizer hope to conduct studies on a large scale, involving 30,000 participants, within weeks.“We still have a ways to go and we’re testing other candidates as well,” said Philip Dormitzer, the chief scientific officer for viral vaccines at Pfizer’s research laboratories. “However, what we can say at this point is there is a viable candidate based on immunogenicity and early tolerability safety data.”

Ugur Sahin, co-founder, and chief executive of BioNTech said that the company was opting for a higher level of neutralizing antibody responses in order to increase the likelihood that those vaccinated are prevented from spreading the disease, as well as from contracting.

BioNTech and Pfizer expect to manufacture up to 100m doses of the vaccine by the end of the year, and over 1.2bn doses by the end of 2021, counting on the dosage sizes required.

According to the Financial Time, the Pfizer and BioNTech vaccine are based on a technology called messenger RNA (mRNA) - a process that is faster than traditional methods. Instead of using pathogens to induce an immune response, mRNA vaccines use genetic material that carries instructions for cells to produce proteins that fight disease. However, no marketable mRNA product has been produced to date.

2223 11

BioNTech and Pfizer hope to progress to a larger US trial, involving 30,000 participants, within weeks

Photo: Reuters

BioNTech is one of 17 groups to have proceeded to clinical evaluation of a Covid-19 vaccine, according to the World Health Organization.

BioNTech on Monday explored whether its technologies could be used as a Covid-19 therapy, adding that it had raised $250m from Temasek, the investment vehicle of the Singaporean government, alongside other investors. The company has also secured €100m in loans from the European Investment Bank.

Fourteen Covid-19 vaccines are currently in human trials, according to the Milken Institute, including entrants from Inovio, CanSino, AstraZeneca, and Moderna. More are expected to start soon, including entrants from Merck, Johnson & Johnson, and Sanofi. In total, 178 vaccines are in various stages of development, reported the Stat News.

The Mainz-based company, which has also partnered with Chinese company Fosun, is experimenting with four variants of its vaccine technology and has been running another clinical trial in Germany since April. The company plans to carry out the third study in Asia within weeks.

Last month, local rival CureVac, which is also developing an mRNA-based Covid-19 vaccine, received €300m in funding from the German government, following reports that the Trump administration had sought to secure supply of the product exclusively for the US.

asean australia coordinate closely to develop covid 19 vaccines medicine ASEAN, Australia coordinate closely to develop COVID-19 vaccines, medicine

Foreign ministers of ASEAN member countries and Australia agreed to coordinate closely to develop and produce COVID-19 vaccines and medicine.

us news today june 30 coronavirus drugs price sparks affordability questions concerns US News today, June 30: Coronavirus drug's price sparks affordability questions, concerns

One teen killed and another injured in shooting in Capitol Hill Organized Protest zone, Supreme Court to block controversial Louisiana abortion law, coronavirus drug's price sparks affordability questions, concerns ...

india first covid 19 vaccine gets approval for human trials India: First COVID-19 vaccine gets approval for human trials

Permission was granted after the firm submitted results from pre-clinical studies of the vaccine that demonstrated its safety and immune response, said Bharat Biot

Malie Nguyen
Phiên bản di động